

Date: July 24, 2023

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex, Bandra
(East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Notice of the meeting of the Committee of Directors (Rights Issue) of Piramal Pharma Limited (“Company”) dated July 27, 2023, pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)

Dear Sir/Madam,

This is with reference to our intimation on the outcome of the meeting of the board of directors of the Company (“**Board**”) dated February 8, 2023, where the issue of fully paid-up equity shares of the Company of face value of ₹10 each (“**Equity Shares**”) was approved by way of a rights issue for an amount not exceeding ₹1,050 crores (“**Rights Issue**”), in accordance with the Companies Act, 2013, as amended and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws.

This is to inform you that a meeting of the Committee of Directors (Rights Issue) is proposed to be held on July 27, 2023 *inter alia*, to consider various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the Rights Issue price, rights entitlement ratio and the record date.

This intimation is issued in terms of the applicable provisions of the SEBI Listing Regulations.

You are requested to kindly take note of the same.

For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN : U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

piramal.com